US FDA approves ImmunityBio's bladder cancer therapy
The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
Google News
RSS
Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.
By submitting, you agree that we may use your email address to respond.
